Sartorius Stedim Biotech (OTCMKTS: SDMHF) is a leading provider of bioprocess solutions for the life science and pharmaceutical industries. Headquartered in Aubagne, France, the company specializes in the design, development and manufacturing of equipment and consumables for drug substance production. Its product portfolio spans single‐use bioreactors, filtration systems, chromatography modules, cell culture media and buffer preparations, all designed to support the development and large‐scale manufacture of vaccines, monoclonal antibodies and other biologics.
Since its origins in the 1990s as part of the Sartorius Group, the Stedim Biotech division has grown through a combination of in-house innovation and strategic acquisitions to address evolving customer needs. The company emphasizes single‐use technologies to reduce cross-contamination risk, accelerate process scale-up and lower overall production costs. Its comprehensive offering also includes process engineering services, automation software and process analytics, enabling end-to-end support from cell line development through commercial manufacturing.
Sartorius Stedim Biotech maintains a global footprint, with manufacturing sites in Europe, North America and Asia and a network of subsidiaries serving customers in over 110 countries. Its solutions are used by multinational pharmaceutical companies, contract development and manufacturing organizations (CDMOs) and academic research institutions. The company collaborates closely with clients to tailor bioprocess workflows, drawing on expertise in regulatory compliance, quality assurance and process optimization to help bring new therapies from concept to market.
AI Generated. May Contain Errors.
Free SDMHF Stock Alerts